Richard Epstein, PhD, Economist from the University of Chicago in the Wall Street Journal reviews the importance of off-label uses of approved medications for cancer patients. He makes a compelling case that for cancer drugs that have made it past phase I, it would be beneficial for the major cancer centers to have access to these medications for experimental last ditch therapies.
The FDA should consider expediting its review process for cancer medications that are vital to save patients lives, many of which have relatively few options.